Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone. The ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Pre-Market: 7:00:00 a.m. EDT Loading Chart for TEVA ...

Michael L. Krychman, MD; Jan L. Shifren, MD, NCMP; James H. Liu, MD; Sheryl L. Kingsberg, PhD; Wulf H. Utian, MB BCh, PhD, DSc(Med), FRCOG, FACOG, FICS ...

As of March 17 at 4:00:00 PM EDT. Market Open. Loading Chart for HLBBF ...